Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV

By sjmartinez • January 2, 2025

Fairlie L, Brummel S, Ziemba L, Coletti A, Chinula L, Shapiro R, Stringer J, Malonga G, Browning R, Chakhtoura N, Mmbaga BT, Mhembere TP, Omoz-Oarhe A, Nagaddya B, Naidoo M, Hoffman RM, Lockman S; IMPAACT 2010/VESTED Study Team. Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV. J Acquir Immune Defic Syndr. 2024 Oct;97(2):150-155. doi: 10.1097/qai.0000000000003473. PMID: 39742354; PMCID: PMC11684739.

Tags: Conception on antiretroviral therapy, high rates adverse outcomes, Infectious Diseases, interpregnancy interval, pregnancy outcomes, prior pregnancy loss, Publications, Women living with HIV

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

Gebremariam T, Gu Y, Patterson H, Youssef E, Alkhazraji S, Elsayed T, Wiederhold NP, Ibrahim AS. Efficacy assessments of SF001, a next-generation polyene antifungal, in[...]

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

Dao KT, D'Assumpcao C, Sharma R, Singh C, Kuran R, Heidari A. Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Cureus. 2025 Feb 24;17(2):e79588.[...]

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes[...]